Nicholas A Tritos1,2, Beverly M K Biller3,4. 1. Neuroendocrine Unit, Massachusetts General Hospital, Zero Emerson Place # 112, Boston, MA, 02114, USA. ntritos@partners.org. 2. Harvard Medical School, Boston, MA, USA. ntritos@partners.org. 3. Neuroendocrine Unit, Massachusetts General Hospital, Zero Emerson Place # 112, Boston, MA, 02114, USA. 4. Harvard Medical School, Boston, MA, USA.
Abstract
PURPOSE: To review published data on pegvisomant and its therapeutic role in acromegaly. METHODS: Electronic searches of the published literature were conducted using the keywords: acromegaly, growth hormone (GH) receptor (antagonist), pegvisomant, therapy. Relevant articles (n = 141) were retrieved and considered for inclusion in this manuscript. RESULTS: Pegvisomant is a genetically engineered, recombinant growth hormone receptor antagonist, which is effective in normalizing serum insulin-like growth factor 1 (IGF-1) levels in the majority of patients with acromegaly and ameliorating symptoms and signs associated with GH excess. Pegvisomant does not have direct antiproliferative effects on the underlying somatotroph pituitary adenoma, which is the etiology of GH excess in the vast majority of patients with acromegaly. Therefore, patients receiving pegvisomant monotherapy require regular pituitary imaging in order to monitor for possible increase in tumor size. Adverse events in patients on pegvisomant therapy include skin rashes, lipohypertrophy at injection sites, and idiosyncratic liver toxicity (generally asymptomatic transaminitis that is reversible upon drug discontinuation), thus necessitating regular patient monitoring. CONCLUSIONS: Pegvisomant is an effective therapeutic agent in patients with acromegaly who are not in remission after undergoing pituitary surgery. It mitigates excess GH action, as demonstrated by IGF-1 normalization, but has no direct effects on pituitary tumors causing acromegaly. Regular surveillance for possible tumor growth and adverse effects (hepatotoxicity, skin manifestations) is warranted.
PURPOSE: To review published data on pegvisomant and its therapeutic role in acromegaly. METHODS: Electronic searches of the published literature were conducted using the keywords: acromegaly, growth hormone (GH) receptor (antagonist), pegvisomant, therapy. Relevant articles (n = 141) were retrieved and considered for inclusion in this manuscript. RESULTS:Pegvisomant is a genetically engineered, recombinant growth hormone receptor antagonist, which is effective in normalizing serum insulin-like growth factor 1 (IGF-1) levels in the majority of patients with acromegaly and ameliorating symptoms and signs associated with GH excess. Pegvisomant does not have direct antiproliferative effects on the underlying somatotroph pituitary adenoma, which is the etiology of GH excess in the vast majority of patients with acromegaly. Therefore, patients receiving pegvisomant monotherapy require regular pituitary imaging in order to monitor for possible increase in tumor size. Adverse events in patients on pegvisomant therapy include skin rashes, lipohypertrophy at injection sites, and idiosyncratic liver toxicity (generally asymptomatic transaminitis that is reversible upon drug discontinuation), thus necessitating regular patient monitoring. CONCLUSIONS:Pegvisomant is an effective therapeutic agent in patients with acromegaly who are not in remission after undergoing pituitary surgery. It mitigates excess GH action, as demonstrated by IGF-1 normalization, but has no direct effects on pituitary tumors causing acromegaly. Regular surveillance for possible tumor growth and adverse effects (hepatotoxicity, skin manifestations) is warranted.
Authors: A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner Journal: Lancet Date: 2001-11-24 Impact factor: 79.321
Authors: Albert Beckers; Maya Beth Lodish; Giampaolo Trivellin; Liliya Rostomyan; Misu Lee; Fabio R Faucz; Bo Yuan; Catherine S Choong; Jean-Hubert Caberg; Elisa Verrua; Luciana Ansaneli Naves; Tim D Cheetham; Jacques Young; Philippe A Lysy; Patrick Petrossians; Andrew Cotterill; Nalini Samir Shah; Daniel Metzger; Emilie Castermans; Maria Rosaria Ambrosio; Chiara Villa; Natalia Strebkova; Nadia Mazerkina; Stéphan Gaillard; Gustavo Barcelos Barra; Luis Augusto Casulari; Sebastian J Neggers; Roberto Salvatori; Marie-Lise Jaffrain-Rea; Margaret Zacharin; Beatriz Lecumberri Santamaria; Sabina Zacharieva; Ee Mun Lim; Giovanna Mantovani; Maria Chaira Zatelli; Michael T Collins; Jean-François Bonneville; Martha Quezado; Prashant Chittiboina; Edward H Oldfield; Vincent Bours; Pengfei Liu; Wouter W de Herder; Natalia Pellegata; James R Lupski; Adrian F Daly; Constantine A Stratakis Journal: Endocr Relat Cancer Date: 2015-02-24 Impact factor: 5.678
Authors: Caroline Sievers; Dorothee M Baur; Anja Schwanke; Michael Buchfelder; Michael Droste; Klaus Mann; Günter K Stalla Journal: Pituitary Date: 2015-12 Impact factor: 4.107
Authors: Michael Droste; Julia Domberg; Michael Buchfelder; Klaus Mann; Anja Schwanke; Günter Stalla; Christian J Strasburger Journal: Eur J Endocrinol Date: 2014-07 Impact factor: 6.664
Authors: Felix Ehret; Markus Kufeld; Christoph Fürweger; Alfred Haidenberger; Paul Windisch; Susanne Fichte; Ralph Lehrke; Carolin Senger; David Kaul; Daniel Rueß; Maximilian Ruge; Christian Schichor; Jörg-Christian Tonn; Günter Stalla; Alexander Muacevic Journal: Cancers (Basel) Date: 2021-01-31 Impact factor: 6.639